[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"catatonia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:catatonia":35},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,58,91,111,130,155],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":36,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100649721","eeg-microstate-and-neuroinflammatory-biomarkers-in-older-age-patients-with-major-depressive-disorder-receiving-ect-100649721",false,"NCT07740694","EEG Microstate and Neuroinflammatory Biomarkers in Older Age Patients With Major Depressive Disorder Receiving ECT","The Relationship Between EEG Microstate Parameters, Neuroinflammatory Biomarkers and Treatment Response in Older Patients With Major Depressive Disorder or Bipolar Disorder Undergoing Electroconvulsive Therapy","Inclusion Criteria:\n\nPatient Group\n\n* Age ≥55 years.\n* Diagnosis of Major Depressive Disorder or Bipolar Disorder, current major depressive episode, according to DSM-5 criteria.\n* Clinical indication for electroconvulsive therapy (ECT).\n* Ability to provide written informed consent.\n* Willingness to participate in the study.\n\nHealthy Control Group:\n\n* Age ≥55 years.\n* No current psychiatric disorder.\n* No known neurological disorder.\n* Good general physical health.\n* No current use of medications known to affect EEG activity or inflammatory biomarkers significantly.\n* Ability to provide written informed consent.\n* Willingness to participate in the study.\n\nExclusion Criteria:\n\n* Primary neurological disorders (e.g., dementia or traumatic brain injury).\n* Schizophrenia or other psychotic disorders.\n* Intracranial space-occupying lesions.\n* Increased intracranial pressure.\n* Myocardial infarction within the previous 3 months.\n* Cerebrovascular disease within the previous month.\n* Unstable cerebral aneurysm.\n* Pheochromocytoma.\n* Electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) within the previous month.\n* Cognitive impairment severe enough to prevent adequate cooperation during EEG recording.\n* Current alcohol or substance use disorder.\n* Active infectious disease.\n* Uncontrolled autoimmune or chronic inflammatory disorders. Participants with stable disease who had received the same maintenance treatment within the previous 3 months were eligible for inclusion.",true,"ALL","55 Years",{"count":20,"type":21},62,"ESTIMATED","OBSERVATIONAL","This study aims to investigate the neurophysiological and inflammatory changes associated with electroconvulsive therapy (ECT) in older age patients diagnosed with Major Depressive Episode, Major Depression, and Bipolar Disorder, using microstate analysis derived from resting-state electroencephalography (EEG) recordings. Within this scope, EEG recordings obtained before and after ECT will be compared to determine the relationships between changes in microstate parameters and inflammatory marker levels, clinical variables, and psychometric scale scores reflecting clinical improvement. Peripheral blood samples collected from the same patient group will be analyzed for complete blood count parameters as well as levels of interleukin-1 alpha (IL-1α), interleukin-1 beta (IL-1β), interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), tumor necrosis factor-alpha (TNF-α), soluble glycoprotein 130 (sgp-130), soluble interleukin-6 receptor (sIL-6R), interferon gamma-induced protein 10 kDa (IP-10), and C-reactive protein (CRP). In addition, inflammatory indices, including the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Monocyte-to-Lymphocyte Ratio (MLR), will be calculated. The association between baseline levels of these biomarkers and treatment response will be evaluated. Moreover, changes in biomarker levels following ECT will be statistically examined in relation to clinical scale scores and EEG microstate parameters. Although microstate analysis and inflammatory biomarkers have each been extensively investigated in psychiatric disorders, studies evaluating these two biomarkers together, particularly with the inclusion of healthy control participants, in the older age population remain limited. In this regard, the present study aims to evaluate the effects of ECT on older age patients using objective neurophysiological indicators, contribute to the understanding of the pathophysiology of depression at the level of brain networks, and provide a scientific basis for the development of personalised treatment approaches in the future.",[25,26,27,28,29,30,31,32,33,34,35],"Major Depression Moderate","Major Depression Severe","Major Depression With Comorbid Anxiety Symptoms","Major Depression With Panic Attacks","Major Depression With Psychotic Features","Major Depressive Episode","Bipolar Affective Disorder","Bipolar Depression Depressed Phase","Bipolar Depression","Bipolar Anhedonic Depression","Catatonia",[37,30,38,39,40,41,42,43,33,44],"ECT","Major Depression","Inflammatory biomarker","EEG","Microstate","Treatment Resistant Depression","Difficult to Treat Depression","Bipolar Disorder","RECRUITING","2026-07-28",{"date":48,"type":49},"2026-07-31","ACTUAL",{"date":51,"type":49},"2025-12-01",{"date":53,"type":21},"2027-02",{"name":55,"class":56},"Istanbul University - Cerrahpasa","OTHER",1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":17,"minAge":65,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":77,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":57},"100650054","treatment-resistance-in-psychiatric-disorders-the-search-for-biological-markers-predictive-of-response-to-treatment-100650054","NCT07741981","Treatment Resistance in Psychiatric Disorders: the Search for Biological Markers Predictive of Response to Treatment","BIO-INM","Inclusion Criteria:\n\n* Patient aged ≥ 18 years old;\n* Patient suffering from a psychiatric disorder according to DSM-5 criteria;\n* Patient with drug-resistant disease according to the definition of the protocol\n* Patient starting a new treatment for his pathology;\n* Patient informed and having signed an informed consent;\n* Patient covered by the social security system.\n\nExclusion Criteria:\n\n* Patient with major neurocognitive disorder diagnosed (dementia syndrome)\n* Pregnant, laboring, or breastfeeding female patients\n* Patient deprived of liberty by judicial or administrative decision. Patient in psychiatric care under constraints may be included.\n* For patients accepting the lumbar punction: patients who are unable to control themselves and are likely to engage in physical or violent behavior.","18 Years",{"count":67,"type":21},700,"INTERVENTIONAL",[70],"NA","The disruption of immune system is a key candidate in the pathogenesis of psychiatric disorders, especially those resistant to traditional treatments. Involving complex processes within the brain and peripheral immune system, inflammation may lead to imbalance of neurotransmitter systems and synaptic plasticity and directly contribute to the psychiatric symptoms observed in conditions such as depression, bipolar disorder (BD) and schizophrenia (SCZ).\n\nStudies show that treatment-resistant depression (TRD) is associated with elevated levels of inflammatory markers in the blood, which are linked to a lower response to conventional antidepressants. Interventions that modulate this inflammatory response, such as immunomodulatory treatments or therapies targeting pro-inflammatory cytokines, have demonstrated beneficial effects by reducing symptoms and improving patients' quality of life.\n\nA thorough understanding of the links between inflammation and treatment resistance therefore paves the way for innovative therapeutic strategies. These approaches could transform current practices by offering more personalized and effective solutions for patients suffering from chronic and resistant psychiatric disorders.",[73,74,75,35,76],"Schizophrenia","Treatment Resistant Depression (TRD)","Bipolar Disorder (BD)","Obsessive Compulsive Disorder (OCD)",[78,79,80],"biomarkers","treatment resistance","response prediction","NOT_YET_RECRUITING","2026-07-27",{"date":84,"type":49},"2026-08-03",{"date":86,"type":21},"2026-07-15",{"date":88,"type":21},"2038-08-01",{"name":90,"class":56},"Centre Hospitalier St Anne",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":17,"minAge":65,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":57},"100403241","blood-concentration-in-lorazepam-and-treatment-in-adult-catatonia-100403241","NCT04530734","Blood Concentration in Lorazepam and Treatment in Adult Catatonia","PHARMAPREDICAT","Inclusion Criteria:\n\n* catatonia according DSM-5\n\nExclusion Criteria:\n\n* Subject is less than 18 years of age\n* Subject is pregnant at the time of the study\n* Subject\u002Flegal guardian unwilling to participate in the study",{"count":99,"type":21},100,"Catatonia is a severe form of psychomotor disturbance with a heterogenous presentation. It affects approximately 10% of acute psychiatric inpatients. According to the fifth edition of DSM-5 the diagnosis of catatonia can be made when three or more symptoms from the twelve following are present : catalepsy, waxy flexibility, stupor, agitation, mutism, negativism, posturing, mannerisms, stereotypies, grimacing, echolalia, echopraxia. It can occur in various psychiatric diseases, including mood disorders or schizophrenia, but also in various non-psychiatric disorders \\[metabolic disturbances, viral infections (including HIV), typhoid fever, heat stroke, and autoimmune disease\\].\n\nBenzodiazepines, especially LORAZEPAM, are the most common initial treatment, with a remission rate of approximately 70-80 %, regardless of the cause or the clinical manifestations. This first line treatment is titrated gradually according to the therapeutic response over a few days up to 20-25 mg per day. Electroconvulsive therapy (ECT) is initiated on patients with catatonia who do not respond to benzodiazepines.\n\nInterestingly, pharmacogenetic variants can alter the metabolism of lorazepam (e.g., the UGT2B15 \\* 2 allele slows it down).\n\nThe main objective of this study is to assess the link between clinical response to lorazepam, residual plasma concentrations of lorazepam after 72 hours of fixed dosage, and the existence of genetic polymorphisms modifying the metabolism of lorazepam. Our hypothesis is that non-responding patients have lowered blood concentrations of lorazepam associated to a genetic profile of rapid metabolism. Evaluating the predictive factors of the response to treatment would allow early and precise identification of non-responder patients in order to adapt their first-line treatment.",[35],"2026-05-20",{"date":104,"type":49},"2026-05-22",{"date":106,"type":49},"2020-01-01",{"date":108,"type":21},"2027-01",{"name":110,"class":56},"University Hospital, Lille",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":65,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":57},"100617189","catatonic-syndrome-in-adult-patients-at-basurto-hospital-a-descriptive-study-of-incidence-comorbidity-and-short-term-outcomes-100617189","NCT07315386","Catatonic Syndrome in Adult Patients at Basurto Hospital: A Descriptive Study of Incidence, Comorbidity, and Short-Term Outcomes","Inclusion Criteria\n\n* Age ≥ 18 years at the time of hospital care.\n* Diagnosis of catatonic syndrome established according to DSM-5 criteria.\n* Patients attended at Basurto University Hospital in any clinical setting, including the Emergency Department or inpatient physical or psychiatric units.\n* Diagnosis made during the study period, from 1 January 2024 to 31 December 2025.\n* Catatonia of any etiology, including psychiatric, neurological, medical, metabolic, toxic, or autoimmune causes.\n* Provision of informed consent by the patient or their legal representative, when clinically feasible; deferred consent accepted in cases of acute catatonia.\n\nExclusion Criteria\n\n* Refusal to participate in the study by the patient or their legal representative.\n* Withdrawal of informed consent at any point during the study.",{"count":118,"type":21},40,"This study aims to assess the incidence, sociodemographic and clinical characteristics, treatment response, and short-term outcomes of adult patients with catatonic syndrome in the Bilbao area (Spain). Data will be collected from January 2024 to December 2025 from all patients aged 18 years or older diagnosed with catatonia of any etiology at Basurto University Hospital who provide informed consent to participate.",[35],"2026-05-11",{"date":123,"type":49},"2026-05-12",{"date":125,"type":49},"2024-01-01",{"date":127,"type":21},"2030-12-31",{"name":129,"class":56},"Beatriz Rodriguez Cabo",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":68,"phases":140,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":57},"100636101","optimizing-stimulation-parameters-for-electroconvulsive-therapy-100636101","NCT07561307","Optimizing Stimulation Parameters for Electroconvulsive Therapy","Parameter Refinement for ECT Stimulation and Titration Optimization","PRESTO","Inclusion Criteria:\n\n* Any patients being treated with electroconvulsive therapy at Pennsylvania Hospital who are willing and able to participate are eligible to be subjects in this study.\n\nExclusion Criteria:\n\n1. They are unwilling or unable to consent first to the SWEET COMBO protocol for optical monitoring during ECT\n2. Clinically significant psychiatric comorbidity as determined by clinical interview and in the opinion of the Investigator and clinical team would alter the risk\u002Fbenefit of the study\n3. History of poor response to ECT treatment in the opinion of the Investigator and clinical team that would alter the risk\u002Fbenefit of the study\n4. Presence of any disease, medical condition or physical condition that, in the opinion of the Investigator, may compromise, interfere with, limit, affect or reduce the:\n\n   1. subject's ability to participate safely in the study\n   2. integrity of the data or\n   3. subject's ability to complete the full duration of the study.",{"count":139,"type":21},64,[70],"The goal of this clinical trial is to improve how electroconvulsive therapy (ECT) stimulation settings are chosen. Researchers will use real-time brain monitoring to measure both seizures and a recently identified brain event called cortical spreading depolarization (CSD).\n\nThe main questions it aims to answer are:\n\nWhat is the best way to increase ECT stimulation settings? How do different pulse settings affect the brain's response? Can certain settings produce CSD without causing a seizure?\n\nParticipants already receiving ECT as part of their care will take part. They will be assigned to one of two groups:\n\nIndex ECT group: Participants starting ECT will receive different standard titration approaches.\n\nMaintenance ECT group: Participants receiving ongoing ECT will undergo a brief, low-dose stimulation test before treatment.\n\nAll participants will be monitored using brain physiology (EEG and blood flow) and symptom scales during treatment.",[143,35],"Depression - Major Depressive Disorder",[145],"electroconvulsive therapy","2026-04-23",{"date":148,"type":49},"2026-05-01",{"date":150,"type":21},"2026-07-01",{"date":152,"type":21},"2030-06-30",{"name":154,"class":56},"University of Pennsylvania",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":17,"minAge":161,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":68,"phases":165,"briefSummary":166,"conditions":167,"keywords":168,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":4},"100566545","immunogenomic-analyses-of-pediatric-catatonia-100566545","NCT06656572","Immunogenomic Analyses of Pediatric Catatonia","Inclusion Criteria:\n\n* Individual in whom one of the following criteria is met:\n\n  1. Child\u002Fadolescent Ages 0-17 (2) with a diagnosis of catatonia.\n\n     OR\n  2. Biological parents of child\u002Fadolescent enrolled in this study for the purposes of reflex testing. Family members are eligible for participation in this study if they are presumed to be genetically related to a patient participant\n\nExclusion Criteria:\n\n* Child\u002Fadolescents patients who do not meet any of the inclusion criteria, or those who:\n\n  1. Already received any prior whole genome sequencing or exome sequencing.\n  2. Unable to approach the family or patient for enrollment.\n  3. Unable to obtain informed consent.\n  4. Family members are ineligible for participation in this study if:\n\n     1. They are known to not be genetically related to the child\u002Fadolescent patient participant","0 Years","17 Years",{"count":164,"type":21},120,[70],"Rady Children's Institute for Genomic Medicine seeks to understand the genomes and immune systems in 40 children and adolescents who are admitted to Rady Children's Hospital San Diego with a catatonia diagnosis. Cutting-edge genome and protein sequencing technology will be used to better understand how immunological and genetic assessments may improve the ability to identify the cause of catatonia and impact care. The investigator also hopes to identify new genetic and\u002For autoimmune causes of catatonia that may inform new treatment for future patients.",[35],[169,170],"Genomics","Pediatric","2024-11-12",{"date":173,"type":49},"2024-11-14",{"date":175,"type":21},"2024-12-01",{"date":177,"type":21},"2030-09-01",{"name":179,"class":56},"Rady Pediatric Genomics & Systems Medicine Institute"]